Dianalitics
Femasys Inc.
FEMY · v8 · 2026-06-08
arrow_back
homeHomemonitoringPerformancesearch
hourglass
Loading…
Preparing the latest DD data, styles and content.
31RiskyDD: Jun 08, 2026Analyst: 29
paidPrice at analysis date
USD 5.87 (08/06/2026)
domainMkt cap
$18M
pie_chartShares
3.02M
candlestick_chart52W
$5.71-$22.20
trending_downShort interest
3%
HIGHNasdaq Capital MarketHealth Care69 employeesFounded 2004
Verdict: HIGH RISK — Going concern + dilution overhang

Pre-commercial women's-health medtech with FDA-cleared portfolio (FemBloc permanent birth control in pivotal trial, FemaSeed fertility, FemVue diagnostic). Cash $5.4M and Q1 burn $4.1M imply runway only into Q3 2026 — going concern explicit. Just executed 1-for-20 reverse split (effective 2026-06-05) to maintain Nasdaq listing. Convertible notes and warrant tranches threaten material dilution. Equity is a binary bet on FemBloc trial success + ability to raise capital without crushing existing holders.

📊 DIANALITICS RESEARCH INDEXCompany & Thesis Assessment Score /100 — updated 2026-06-08
29
Femasys Inc. (FEMY)
Women's Health Medtech · NASDAQ · Suwanee, GA
"Binary asymmetric bet — capital constraint dominates IP value"
Going concern Dilution overhang Reverse-split FDA pivotal in progress Women's health TAM
Fin. strength
2
/20 pts
EBITDA/FCF
1
/15 pts
Debt/leverage
4
/15 pts
Stage/business
5
/15 pts
Catalysts
6
/10 pts
Reg. risk
2
/8 pts
Risk/reward
4
/7 pts
Management
2
/5 pts
Sector/macro
2
/3 pts
Compliance
1
/2 pts
💡 Fair Value estimate — rNPV pipeline + cash floor − dilution (post-split basis)
Fair value base case
USD 4.80
Range: USD 1.50-USD 18.0
Price at analysis date: USD 5.87 (08/06/2026)
Base upside/downside: -18%

Methodology: rNPV applied to two main pipeline assets (FemBloc, FemaSeed) using conservative peak-sales × revenue multiple, risk-adjusted by probability of approval and discounted to present; fully-diluted share count assumes 6M (3M current basic + 0.82M from converts + ~2.2M from next raise). Implied multiple of ~6× forward revenue is at the high end of peer range — sensitivity: ±2× moves FV by ±$3/sh. If the next equity raise is structured as a death-spiral convertible (i.e. variable conversion ratio), the FD share count assumption (6M) is materially understated and FV would compress 30-50% further. Bear weight at 50% reflects ~3 quarters of going-concern history without resolution and the explicit warning in the 10-Q. ⚠️ Not investment advice.

ComponentAssumptionUSD/share
Cash floor$5.4M cash @ 31 Mar 2026 / 3.02M post-split shares+1.79
FemBloc rNPV (US)Peak sales $180M × 30% PoS × 6× rev multiple / 8% discount × 6 yrs to launch ≈ $50M risk-adj NPV / 6M fully-diluted shares+8.30
FemaSeed commercial rampPeak sales $60M × 60% PoS (already FDA-cleared) × 4× / discounted ≈ $18M / 6M FD shares+3.00
FemVue + intl portfolio$1.5M revenue × 3× sales / 6M FD shares (existing commercial base)+0.75
Convertible note dilution−0.82M post-split shares ITM at $14.60 strike, reduces per-share value by ~21% (already in 6M FD denominator above)−2.50
Next-round equity raise haircutNeed ~$20M to fund through 2027 milestones; modeled at 50% discount to current → ~2.5M new shares × $3 = $7.5M raised (insufficient) → 75% expected dilution baked into FD count + −20% per-share haircut−6.54
FV base caseSum of rows above≈ $4.80
Bull
$14 – $18
Probability: 15%
FemBloc FINALE trial enrolls smoothly through 2027, positive interim, strategic partner (Hologic, Organon, Cooper) signs licensing deal $40-80M upfront; capital raise priced near current with reasonable warrant coverage; FemaSeed reimbursement (CPT Cat III effective 2027) ramps revenue toward $5-8M.
Base
$3 – $7
Probability: 35%
Capital raise within 60-90 days at 30-50% discount, additional ~2-3M post-split shares issued; FemBloc trial continues to plan but readout slips to 2028; FemaSeed grows but stays sub-$3M; stock oscillates in single digits as dilution and milestones compete.
Bear
$1 – $3
Probability: 50%
Cash crisis forces emergency financing at deep discount (Yorkville / SPA / death-spiral structure); FemBloc trial enrollment slips; second Nasdaq compliance failure requires further reverse split or delisting; option value collapses toward residual cash floor net of warrant cash.
Methodology: Methodology: rNPV applied to two main pipeline assets (FemBloc, FemaSeed) using conservative peak-sales × revenue multiple, risk-adjusted by probability of approval and discounted to present; fully-diluted share count assumes 6M (3M current basic + 0.82M from converts + ~2.2M from next raise). Implied multiple of ~6× forward revenue is at the high end of peer range — sensitivity: ±2× moves FV by ±$3/sh. If the next equity raise is structured as a death-spiral convertible (i.e. variable conversion ratio), the FD share count assumption (6M) is materially understated and FV would compress 30-50% further. Bear weight at 50% reflects ~3 quarters of going-concern history without resolution and the explicit warning in the 10-Q. ⚠️ Not investment advice. Not investment advice.
warning
🚨 GOING CONCERN + IMMINENT DILUTION + RECENT REVERSE SPLIT
Management has explicitly disclosed substantial doubt about ability to continue as a going concern: current cash ($5.4M at 31 Mar 2026) and expected revenues fund operations only into Q3 2026. Convertible notes issued Nov 2025 are convertible into up to 16.4M pre-split shares at $0.73 (≈ 0.82M post-split shares at $14.60 post-split); warrant tranches at $0.81 / $0.92 / $1.10 pre-split (≈ $16.20 / $18.40 / $22.00 post-split) carry anti-dilution adjustments. Capital raise is virtually certain within 60-90 days; structure and price unknown. 1-for-20 reverse split effective 2026-06-05 to regain $1 Nasdaq minimum bid (compliance deadline 13 Jul 2026).
⚠️ Methodology note: FEMY is a distressed pre-commercial medtech with going concern. Fair value built bottom-up using rNPV for FemBloc/FemaSeed pipeline + cash floor minus dilution overhang, NOT EV/EBITDA multiples (negative EBITDA, immaterial revenue). All per-share figures expressed on a post-split basis (1-for-20 reverse split effective 2026-06-05). Pre-split historical prices and conversion strikes were rescaled ×20 for consistency.
📊 Capital Structure · Short Interest · Buyback & Dilution
⚪ Short Interest
N/D
Reliable short interest data not available post-reverse-split (settlement of borrow positions still in progress). Pre-split short interest was sub-3% — uneconomic to short a $0.30 stock; reverse split itself rarely triggers fresh shorting.
🔴 Share dilution (1Y)
+~30%
From ~46M pre-split shares (mid-2025) to ~60.4M pre-split (31 Mar 2026). Sources: Nov 2025 $12M convertible + warrants, ATM facility (624K shares for $353K in Q1 2026), reverse-split to maintain Nasdaq compliance. Convertible notes can issue ~16.4M more pre-split shares = +27% additional dilution if fully converted.
🔴 Buyback
$0
No buyback program. Capital allocation 100% absorbed by operating burn ($4.1M/qtr) and clinical trial costs. Priority is cash preservation; next $20M raise is the operative question, not returns to shareholders.
Short Interest — context
FEMY — N/D (post-split)
N/D

For nano-caps with going-concern warnings, the dominant downward pressure is not short interest but the warrant/convertible overhang: holders convert and immediately monetize into thin liquidity, producing structural one-way flow. FEMY post-split float of ~3M shares and average dollar volume of well under $1M/day means even modest share issuance moves the price disproportionately.

$Financial analysis — FY 2025-2026
Q1 2026 Revenue
$0.42M
+24.5% YoY — FemVue driven
Cash @ 31 Mar 2026
$5.4M
−42% vs Dec 2025 ($9.3M)
Q1 2026 Cash burn
$4.1M
Runway into Q3 2026 only
Q1 2026 Op Loss
−$4.1M
R&D cut to $1.3M (−56% YoY)
ItemFY 2023FY 2024FY 2025Q1 2026Guidance 2026
Revenue ($M)1.01.21.50.42No formal guidance
Net loss ($M)−14.5−13.8−13.2+0.85*Loss expected to continue
R&D expense ($M)6.57.210.51.3Reduced to preserve cash
Cash ($M, end of period)11.514.09.35.4Need raise before Q3 2026 close
Shares outstanding (pre-split, M)30.534.254.060.4+ converts/warrants → 80M+ pre-split
*Q1 2026 net income was driven entirely by $5.07M non-cash fair-value gain on the 2025 convertible note conversion option and warrant liability remeasurement. Operating loss remained ~$4.1M. This is an accounting artifact, not improved economics.
Quarterly dynamics — last 5 quarters
MetricQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Revenue ($M)0.340.380.420.400.42
Operating loss ($M)−3.2−3.5−3.4−3.1−4.1
Net loss / income ($M)−3.5−3.7−3.6−2.7+0.85*
End-of-period cash ($M)12.49.16.59.35.4
Financial position and sustainability
Cash runway (months)
~4 mo
Operating margin (Q1 2026)
−965%
FemBloc trial completion (US pivotal)
~15%
Dilution since IPO (2021 → today, pre-split)
+~340%
account_tree

Business model — In-office women's health diagnostics & therapy

Pioneer of office-based, single-use women's-health devices
Femasys designs and develops innovative single-use medical devices that aim to transform fertility care and permanent contraception by moving procedures from operating rooms / specialty clinics into the OB-GYN office. FDA-cleared portfolio includes FemVue (saline-air contrast for HSG imaging), FemCath (selective catheterization), FemCerv (cervical biopsy). Pipeline pivotal asset is FemBloc — a non-surgical permanent birth control device intended as a less-invasive alternative to tubal ligation. FemaSeed is an in-office intrauterine insemination device positioned as a first-line fertility treatment ahead of IVF referral. Business model is medical-device sale + recurring single-use revenue; commercial revenue today is immaterial (~$1.5M TTM) but the platform thesis depends on FemBloc obtaining US FDA approval.

FemBloc (permanent birth control) ~$0M FY26E (pre-commercial US) 🟡 pivotal trial Non-surgical, in-office tubal occlusion alternative. FINALE US pivotal enrollment began Mar 2026; MDSAP certification achieved for US, Canada, Japan, Australia, Brazil. Closest binary catalyst — peak US sales potential $150-250M if approved with broad label. FemaSeed (in-office fertility) ~$0.5M FY26E (early commercial) 🟢 ramping FDA-cleared. Category III CPT code effective 1 Jan 2027 — meaningful reimbursement gating. Targets OB-GYN office as alternative to specialty fertility clinic. Modest near-term revenue; longer-term peak $50-80M with reimbursement. FemVue + diagnostic portfolio ~$1.5-2.0M FY26E (commercial) 🟢 ramping FemVue (saline-air HSG), FemCath, FemCerv. Existing commercial product family; provides revenue base but insufficient to fund operations. Q1 2026 revenue $0.42M (+24.5% YoY) driven mainly by FemVue.

Geographic execution: Feb 2026 partnership with Swiss distributor extended European footprint for FemBloc, FemaSeed and existing portfolio; a $500K second order from France/Benelux partner announced in 2026 is the first material international revenue signal. International revenue stack helps narrative but does not materially close the going-concern gap.

gavel

Legal, regulatory and risk analysis

Going concern
Critical
10-Q explicit: cash + expected revenues fund operations into Q3 2026 only. Without a successful equity raise in the next 60-90 days, FEMY enters technical insolvency. This is the single risk that subsumes all others.
Dilution overhang (convertible notes + warrants)
Critical
Nov 2025 convertible notes convertible into 16.4M pre-split shares at $0.73 (≈ $14.60 post-split). Warrant tranches potentially raise up to $58M total. Anti-dilution adjustments amplify dilution if next raise prices below the strikes.
FemBloc FDA pivotal binary
High
FINALE trial enrollment started Mar 2026. Readout likely 2027-2028. Failure scenarios: enrollment delays, safety signal, efficacy below permanent-contraception threshold. Without FemBloc, FV collapses to cash + FemaSeed.
Nasdaq listing compliance
High
1-for-20 reverse split executed 2026-06-05 to regain $1 minimum bid by 13 Jul 2026 deadline. If post-split price drifts below $1 again (i.e. additional 80%+ drop), delisting risk reactivates with no further extensions likely.
Reimbursement & commercial uptake
Moderate
FemaSeed Category III CPT code is the lowest reimbursement tier; payer coverage is uncertain. FemBloc post-approval will require similar payer engagement against entrenched tubal-ligation alternatives.
Limited litigation; CFPB-style headline risk
Low
No material class action or short-seller campaign identified in 12 months. Insider Form 4 activity is routine compensation grants (e.g. director Eichenbaum 35,200 shares Mar 2026); no open-market selling or pump-and-dump pattern.
Women's-health tailwind
Positive
Femtech and women's-health TAM is under-served and politically/secularly tailwinded post-Dobbs. Office-based shift from inpatient/OR is a credible delivery model with payer and physician interest.
Strategic optionality (M&A target)
Positive
FemBloc + FemaSeed + global regulatory clearances would be strategically valuable to Hologic, Organon, Cooper Companies, Boston Scientific. Distressed valuation makes FEMY a low-cost optionality bet for a strategic acquirer at post-pivotal readout.
article

SWOT analysis

Strengths
  • +FDA-cleared commercial portfolio (FemVue, FemCath, FemCerv) provides ARR base.
  • +FemBloc differentiated as the only non-surgical permanent birth control in late-stage US trial.
  • +Global regulatory footprint via MDSAP certification (US, Canada, Japan, Australia, Brazil).
  • +Long-tenured founder-CEO (Dr Kathy Lee-Sepsick); deep IP portfolio in women's health.
Weaknesses
  • −Cash runway only into Q3 2026; going concern explicitly disclosed.
  • −Revenue immaterial vs cost base (Q1 2026 rev $0.42M vs op loss $4.1M).
  • −Substantial accumulated dilution + convertible/warrant overhang.
  • −Nasdaq compliance fragility (just executed 1-for-20 reverse split).
Opportunities
  • →FemBloc pivotal success in 2027-2028 → strategic licensing or buyout.
  • →FemaSeed Category III CPT (Jan 2027) → payer coverage and revenue ramp.
  • →EU/global commercial expansion via distributor model with limited cash outlay.
  • →Acquisition target for Hologic / Organon / Cooper at distressed valuation.
Threats
  • !Forced emergency financing at deep discount (death-spiral risk).
  • !FemBloc pivotal slip / failure → option value resets to near zero.
  • !Repeat Nasdaq compliance failure post-reverse-split → delisting + liquidity collapse.
  • !Competitive entry (e.g. new permanent-birth-control devices in EU/US pipelines).
article

Summary by assessment area

🔴 Financial risk — CRITICAL
  • Cash $5.4M, quarterly burn $4.1M → runway into Q3 2026 only.
  • Going concern flagged in 10-Q.
  • Convertible + warrant dilution will dominate equity value math.
🟡 Operational risk — HIGH
  • Pre-commercial revenue base; FemBloc binary catalyst 2027-2028.
  • R&D cut to $1.3M Q1 — trial integrity must be preserved.
  • Commercial team minimal; OB-GYN sales cycle is slow.
🔵 Strategic optionality — MEDIUM
  • FemBloc + FemaSeed + global clearances make FEMY a low-cost M&A target.
  • Strategic partner upfront $40-80M would re-rate equity 3-4×.
  • Asymmetric upside only realizable for holders who survive next dilution event.
Sources & Disclaimer

Sources: Femasys SEC filings (10-Q Q1 2026, 8-K reverse split, 8-K $12M financing Nov 2025, DEF 14A proxy), Stocktitan, BioSpace, GlobeNewswire press releases, Yahoo Finance, Investing.com, TipRanks. Market data — last verified close 2026-06-05 ($5.87 split-adjusted basis on first split-adjusted session 2026-06-08): FEMY ~$5.87, market cap ~$18M (post-split; the $368M figure reported by some data providers reflects stale pre-split data not yet adjusted), 52W range (split-adjusted): $5.71–$22.20, ~3.02M shares outstanding post-split. Short interest: N/D post reverse-split. Q1 2026 revenue $0.42M (+24.5% YoY), cash $5.4M, quarterly burn $4.1M, going concern flagged. ⚠️ This document is for informational purposes only and does not constitute financial or investment advice.